Data investigation
What 262 Trials Say Together
262 trials, 99,791 people, 19 drugs, every result graded. Three of its findings cut against how this field is described, starting with the fact that the drug with the mortality evidence is not the one that takes off the most weight.
The BMJ pooled 262 randomized trials covering 99,791 people and 19 drugs, graded the certainty of every result, and produced the best available answer to which obesity drug is best.[1] Three of its findings cut against how this field is usually described. One is that the drug with the strongest evidence for keeping people alive is not the one that takes off the most weight.
Weight loss at one year
| Drug | Weight difference | 95% CI |
|---|---|---|
| Tirzepatide | −14.9% | −16.0 to −13.9 |
| Cagrilintide–semaglutide (CagriSema) | −14.8% | −16.9 to −12.7 |
| Oral semaglutide | −10.9% | −12.7 to −9.1 |
| Orforglipron | −9.9% | −12.4 to −7.5 |
| Subcutaneous semaglutide | −9.8% | −10.6 to −9.1 |
| Phentermine–topiramate | −8.1% | −9.7 to −6.5 |
The newer agents (ecnoglutide, mazdutide, retatrutide) may reach 13.1% to 14.6%, but at very low to low certainty, which is the analysis’s way of saying the evidence is thin enough that these numbers could move substantially. Carry that grading into any conversation about drugs you cannot yet be prescribed.
The drug with the outcome evidence is not the strongest one
Weight is a proxy. What people want is to live longer and avoid heart attacks. On those outcomes the ranking reorders completely.
| Outcome | Drug | Risk ratio (95% CI) |
|---|---|---|
| All-cause mortality | Subcutaneous semaglutide only | 0.81 (0.72–0.93) |
| Myocardial infarction | Subcutaneous semaglutide only | 0.72 (0.61–0.85) |
| Heart failure | Subcutaneous semaglutide | 0.43 (0.21–0.84) |
| Heart failure | Tirzepatide | 0.49 (0.27–0.88) |
| Kidney failure | None convincingly | — |
The only drug associated with fewer deaths is fifth on the weight-loss table.
The reason the ranking reorders is not mysterious: the drug that has been studied longest in the sickest people has the outcome data. Tirzepatide may well show the same or better in time. Right now it has not, and “loses more weight” and “prevents more deaths” are separate claims requiring separate evidence.
No drug cleared the quality-of-life threshold
Across 43 trials and 45,663 participants, no drug improved quality of life beyond the established threshold for a difference patients notice. Every mean difference came in under 5 points on scales where 10 is the minimally important difference.
That is a pooled average, and single questionnaires can read higher. A 2026 analysis of six tirzepatide trials found physical function 10.10 points better than placebo on the weight-specific IWQOL-Lite-CT, but only 2.26 points better on the general SF-36, with results so inconsistent between trials that its authors urged caution.[4] In SURMOUNT-4, people who stayed on tirzepatide finished 11.1 points ahead of those switched to placebo on the IWQOL-Lite-CT total score.[5] That trial measures what is lost on stopping, in people who had already tolerated the drug. These are different scales and designs, so they qualify the review without overturning it.
That is a striking result for treatments whose entire promise is feeling better, and it independently confirms something we reported from the head-to-head trial, where the mental component of a quality-of-life survey did not significantly improve in either arm over 72 weeks (see the mental health score that did not move). One trial finding that is easy to dismiss. Forty-three trials finding it is not.
It does not mean nobody feels better. It means that across the assembled evidence, the average improvement on validated instruments falls below what researchers had agreed in advance would count as noticeable. It is also a claim about general instruments. In heart failure, where a disease-specific symptom score was used, both drugs tested produced improvements patients would notice (see the one place people felt better).
Bigger effects, bigger costs
The analysis’s own conclusion is that larger benefits are generally accompanied by greater harms and more discontinuation. The specifics bear that out.
- Stopping because of side effects was highest with orforglipron, naltrexone–bupropion and liraglutide, as well as phentermine–topiramate, CagriSema and oral semaglutide (risk ratios 1.9 to 4.2).
- Gastrointestinal events were most increased with naltrexone–bupropion, oral semaglutide, orforglipron and tirzepatide (risk ratios 3.1 to 4.2).
- Fatigue rose with naltrexone–bupropion (risk ratio 8.9, an extra 331 people per 1,000 over a year), orforglipron (3.4, 100 more per 1,000) and CagriSema (3.2, 92 more per 1,000). Treat the first figure with caution: the Contrave label, pooling its placebo-controlled trials, lists fatigue in 4.0% on the drug and 3.4% on placebo, and the review’s abstract does not explain the gap.[3]
- Tirzepatide cut fat mass by the largest margin (25.7%), and lean mass by the largest margin too (8.3%).
Two of those deserve a second look. Orforglipron appears on both the discontinuation and gastrointestinal lists. That matches its own head-to-head trial against oral semaglutide, which found roughly double the dropouts (see the first pill-versus-pill trial). And the tirzepatide body composition row is the muscle question quantified: the drug that removes the most fat also removes the most lean tissue, which is what lean mass on a drug versus dieting examines.
What the subgroups did not show
One quiet finding is useful because it is negative. Subgroup analyses across drug dosages and patient characteristics did not identify credible differences in relative treatment effects. The one exception was that longer trials showed larger weight reductions for subcutaneous semaglutide.
In plain terms, nothing in the evidence suggests that particular kinds of patient respond differently in a way anyone can currently predict. That is the same conclusion reached from a different direction by the genetics work, where real predictors exist and are too small to act on (see the genetics are real, and small).
Frequently Asked Questions
References
- 1.Nong K, Shi Q, Xie X, et al. Comparative effects of drugs for adults with overweight or obesity: systematic review and network meta-analysis BMJ. 2026. PMID: 42419792.
- 2.Wilding JPH, Batterham RL, Calanna S, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity N Engl J Med. 2021. PMID: 33567185.
- 3.Nalpropion Pharmaceuticals CONTRAVE (naltrexone and bupropion) extended-release tablets: prescribing information (section 6.1) DailyMed, U.S. National Library of Medicine. 2025. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=485ff360-32c8-11df-928b-0002a5d5c51b
- 4.Schmidt PHS, de Souza VSN, Machado LG, et al. Tirzepatide on physical function in adults with overweight or obesity: A systematic review and meta-analysis Diabetes Obes Metab. 2026. PMID: 41705736.
- 5.Gibble TH, Cao D, Murphy M, et al. Tirzepatide Associated With Improved Health-Related Quality of Life in Adults With Obesity or Overweight in SURMOUNT-4 Obesity (Silver Spring). 2025. PMID: 40903801.
Compare the sellers
Related research
The Head-to-Head, and What It Settles
751 adults randomized to tirzepatide or semaglutide, each at maximum tolerated dose, for 72 weeks. Tirzepatide produced 20.2% weight loss against 13.7%, and on several other endpoints the answer runs the other way.
7 min read
The Drugs Nobody Writes About
A pharmacovigilance study found muscle atrophy reported disproportionately with semaglutide and tirzepatide. The same table shows two older drugs of the same class reported significantly less often than average.
6 min read
The Diet Advice Nobody Has Tested
Everyone on these drugs is told to hit a protein target, drink more, add fiber. A review of 16 randomized trials of these drugs given alongside dietary guidance concluded that evidence on the optimal nutritional approach remains limited.
7 min read
Does Weight Loss Fake Kidney Numbers?
Estimated kidney function is calculated from creatinine, and creatinine comes from muscle, so weight loss could flatter the number. A trial checked the estimates against a directly measured filtration rate.
7 min read
Newer Is Not Stronger
Survodutide has a new mechanism and phase 3 results in the NEJM. It produced 13.0% weight loss at 76 weeks, and its higher dose caused gut side effects in nearly nine of ten participants while losing only 0.8 points more weight than the lower dose.
7 min read
What Tripling the Dose Buys
A higher semaglutide dose produced 18.7% weight loss against 15.6% on the standard dose. Three extra percentage points is the benefit; the costs are in the safety table.
7 min read
Where to get GLP-1 online, safely: sellers our editors have checked
These are telehealth sellers our editors have checked. For each one we hold a price, the form the drug comes in, and the states it reaches.
No insurance needed · vetted by our editors
Some of the links on this page earn us money. If you sign up with a provider after following one, that provider may pay GLP Watchdog a commission. Learn more
Gala
Moving between compounded and brand without changing seller
From $179/mo
Get started →Embody
A flat compounded tirzepatide or semaglutide price at every dose, from a seller that names its pharmacies
From $79/mo
Get started →Eden
Coverage in all 50 states, which most sellers will not confirm
From $99/mo
Get started →